{
  "id": 6346631,
  "title": "Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock",
  "url": "https://urgent.news/2026/09/08/goldman-sachs-just-added-vertex-pharmaceuticals-to-its-conviction-6346631",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T22:20:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/goldman-sachs-just-added-vertex-pharmaceuticals-its-conviction-list-heres-bull-case-big"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsVertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock",
        "url": "https://urgent.news/2026/09/08/goldman-sachs-just-added-vertex-pharmaceuticals-to-its-conviction",
        "published": "2026-09-08T22:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}